Expenditures for treating schizophrenia: A population-based study of Georgia medicaid recipients

Schizophrenia Bulletin

Volumn 24, Issue 3, 1998, Pages 479-488

  Martin, Bradley C ^a,b   Miller, L Stephen ^a  

^a University of Georgia ^*  (United States)

^b UNIVERSITY OF GEORGIA   (United States)

Author keywords

Cost of illness; Economics; Medicaid

Indexed keywords

CHLORPROMAZINE; CHLORPROTHIXENE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; LOXAPINE; MESORIDAZINE; PERPHENAZINE; PROCHLORPERAZINE MALEATE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE;

ADULT; ARTICLE; CONTROLLED STUDY; COST OF ILLNESS; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; PRIORITY JOURNAL; SCHIZOPHRENIA; UNITED STATES;

EID: 0031846345     PISSN: 05867614     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.schbul.a033342     Document Type: Article

References (26)

1. American Medical Association. Physicians' Current Procedural Terminology. 4th ed. Chicago, IL: The Association, 1992.
2. Andreasen, N.C. Assessment issues and the cost of schizophrenia. Schizophrenia Bulletin, 17(3):475-481, 1991.
3. Andrews, G. The cost of schizophrenia revisited. Schizophrenia Bulletin, 17(3):389-394, 1991.
4. Bright, R.A.; Avorn, J.; and Everitt, D.E. Medicaid data as a resource for epidemiologic studies: Strength and limitations. Journal of Clinical Epidemiology, 42(10):937-942, 1989.
5. Davies, L.M., and Drummond, M.F. Economics and schizophrenia: The real cost. British Journal of Psychiatry, 165(Suppl. 25):18-21, 1994.
6. Evers, S.M.A.A., and Ament, A.J.H.A. Costs of schizophrenia in The Netherlands. Schizophrenia Bulletin, 21(1):141-153, 1995.
7. Georgia Department of Medical Assistance. Georgia Department of Medical Assistance Annual Report. Atlanta, GA: The Department, 1992.
8. Georgia Department of Medical Assistance. Georgia Department of Medical Assistance Annual Report. Atlanta, GA: The Department, 1994.
9. Hall, W.; Goldstein, G.; Andrews, G.; Lapsley, H.; Bartels, R.; and Silove, D. Estimating the economic costs of schizophrenia. Schizophrenia Bulletin, 11(4):598-610, 1985.
10. Keith, S.J.; Regier, D.A.; and Rae, D.S. Schizophrenic disorders. In: Robins, L.N., and Regier, D.A., eds. Psychiatric Disorders in America: The Epidemiologic Catchment Area Study. New York, NY: Free Press, 1991. pp. 11-32.
11. Kotzan, J.A.; McMillan, J.A.; Jankel, C.A.; and Foster, A.L. Initial impact of a Medicaid prior authorization program for NSAID prescriptions. Journal of Research in Pharmaceutical Economics, 5(1):25-41, 1993.
12. Manderscheid, R.W.; Rae, D.S.; Narrow, W.E.; Locke, B.Z.; and Regier, D.A. Congruence of service utilization estimates from the Epidemiologic Catchment Area project and other sources. Archives of General Psychiatry, 50:108-114, 1993.
13. Martin, B.C.; Dorfman, J.A.; McMillan, J.A.; and Jankel, C.A. The prevalence of migraine headache and associations with sex, age, race, and residence: A population-based study of Georgia Medicaid recipients. Clinical Therapeutics, 16:855-872, 1994.
14. Martin, B.C., and McMillan, J.A. The impact of a prescription limit on Medicaid recipients: Effects on cost, therapy, and out-of-pocket expenditures. Medical Care, 24:686-701, 1996.
15. McGuire, T.G. Measuring the economic costs of schizophrenia. Schizophrenia Bulletin, 17(3):375-388, 1991.
16. McKenna, P.J. Schizophrenia and Related Syndromes. New York, NY: Oxford University Press, 1994.
17. Moscarelli, M.; Capri, S.; and Neri, L. Cost evaluation of chronic schizophrenic patients during the first 3 years after the first contact. Schizophrenia Bulletin, 17(3):421-426, 1991.
18. Narrow, W.E.; Regier, D.A.; Rae, D.S.; Manderscheid, R.W.; and Locke, B.Z. Use of services by persons with mental and addictive disorders. Archives of General Psychiatry, 50:95-107, 1993.
19. Ray, W.A., and Griffin, M.R. Use of Medicaid data for pharmacoepidemiology. American Journal of Epidemiology, 129:837-849, 1989.
20. Regier, D.A.; Narrow, W.E.; Rae, D.S.; Manderscheid, R.W.; Locke, B.Z.; and Goodwin, F.K. The de facto U.S. mental and addictive disorders service system: Epidemiologic Catchment Area prospective 1-year prevalence rates of disorders and services. Archives of General Psychiatry, 50:85-94, 1993.
21. Rice, D.P.; Kelman, S.; and Miller, L. Estimates of economic costs of alcohol and drug abuse and mental illness, 1985 and 1988. Public Health Report, 106(3):280-292, May-June 1991.
22. Rice, D.P., and Miller, L.S. The costs of schizophrenia: Assessing the burden. Psychiatric Clinics of North America, 16:413-423, 1993.
23. Rice, D.P., and Miller, L.S. The economic burden of schizophrenia: Conceptual and methodological issues and cost estimates. In: Moscarelli, M.; Rupp, A.; and Sartorius, N., eds. Schizophrenia: Handbook of Mental Health Economics and Health Policy. Vol. 1. New York, NY: John Wiley & Sons, 1996.
24. Rupp, A., and Keith, S.J. The costs of schizophrenia: Assessing the burden. Psychiatric Clinics of North America, 16:413-423, 1993.
25. Soumerai, S.B.; Ross-Degnan, D.; Avorn, J.; McLaughlin, T.J.; and Choodnovsky, I. Effects of Medicaid drug-payment limits on admissions to hospitals and nursing homes. New England Journal of Medicine, 325:1071-1077, 1991.
26. U.S. Department of Health and Human Services. International Classification of Diseases, Clinical Modification: ICD-9-CM, 3rd ed., 9th rev. Washington, DC: U.S. Department of Health and Human Services, Public Health Service, 1989.